Argenx Expands Partnership with Fujifilm Biotechnologies to Enhance Local Medicine Supply

Argenx has expanded its partnership with Fujifilm Biotechnologies to support local-for-local medicine supply. Argenx is a global immunology company focused on developing antibody-based medicines for severe autoimmune diseases. The company is commercializing the first approved neonatal Fc receptor blocker and is evaluating its potential in multiple autoimmune diseases, while also advancing experimental medicines within its therapeutic franchises.

Argenx, a global immunology company specializing in antibody-based medicines for severe autoimmune diseases, has expanded its strategic partnership with Fujifilm Biotechnologies to enhance local-for-local medicine supply. This expansion aims to strengthen Argenx’s global supply chain and support its mission of delivering life-impacting therapies to patients worldwide.

Fujifilm Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, will initiate manufacturing of Argenx’s drug substance for efgartigimod at its Holly Springs, North Carolina, site in 2028. This marks the first global end-to-end program for Fujifilm Biotechnologies utilizing its kojoX™ modular network of facilities, which provides flexible capacity at clinical and commercial scales from its manufacturing sites in the United States, United Kingdom, Denmark, and Japan.

Efgartigimod is a monoclonal antibody (mAb) fragment targeting the neonatal Fc receptor (FcRn) in patients with severe autoimmune diseases. It is approved globally for the treatment of adults with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), both chronic autoimmune neuromuscular diseases characterized by significant muscle weakness.

The expanded partnership will allow Argenx to manufacture medicines in the U.S. for American patients while supporting its broader global reach. The collaboration will leverage Fujifilm Biotechnologies’ global kojoX network, which provides local-for-local supply, manufacturing in close proximity to patients. This approach strengthens supply chain resilience and supports a seamless delivery of critical therapies to patients worldwide.

Lars Petersen, president and chief executive officer of Fujifilm Biotechnologies, stated, “This partnership with Argenx marks our first global end-to-end program in support of a customer utilizing our kojoX modular network of facilities. By expanding manufacturing in the United States, we will help to meet Argenx’ global supply chain needs for efgartigimod.” Filip Borgions, chief technology innovation officer of Argenx, added, “Our expanded partnership with Fujifilm Biotechnologies at its Holly Springs site adds to our existing U.S. manufacturing footprint and further strengthens our global supply chain. The kojoX concept enables consistent capabilities across the U.S. and Europe, allowing us to manufacture medicines in the U.S. for American patients while supporting our broader global reach.”

This strategic move underscores the companies’ commitment to enhancing supply chain agility and ensuring the timely delivery of critical medicines to patients in need.